Alleviating the complexity of rare disease research

Limited access to remote sites and ongoing recruitment shortages are posing significant challenges to the field of rare disease research. Cerba Research aims to deliver certainty in these uncertain times, working in partnership with its clients to shape and advance their complex trials.

The company does so by leveraging Cerba HealthCare’s comprehensive and diverse patient databases and biorepositories across five continents.

AI-driven access to demographically rich data – coupled with the availability of advanced, industry-leading laboratories – saves sponsors and clients significant time and effort. Projects are supported and enabled to move forward in a timely manner while remaining within budget.

Alleviating the complexity of rare disease research

Image Credit: Cerba Research

To date, Cerba has screened 28,496 patients across 4,865 sites spread throughout 62 countries. A total of 24% of the company’s pediatric trials are explicitly focussed on rare diseases, with 34% of its overall trials in rare diseases being multiple myeloma trials.

A further 12% of its trials in rare diseases are leukemia trials, incorporating acute lymphoblastic leukemia, chronic lymphocytic leukemia and acute myeloid leukemia.

Cerba’s clients are given the opportunity to enhance their research with patient- and data-driven insights. A diverse array of services and research capabilities are available for clients working with rare diseases, especially cancers.

Cerba can provide assistance with:

  • Custom assay development
  • Pediatrics
  • AI solutions to locate patients
  • Tailored analysis
  • Flexible solutions
  • Genetics and next-generation sequencing (NGS)

Working alongside Cerba allows organizations to change the shape of their clinical development and bring novel, life-changing therapies to patients worldwide.

About Cerba Research

For over 35 years, Cerba Research has been setting the industry standard for exemplary clinical trial conduct. Today, across five continents, with a focus on precision medicine, we are changing the paradigm of the central lab’s role in complex clinical research.

From protocol inception through development and to market, our passionate experts deliver the highest quality specialized and personalized laboratory and diagnostic solutions. Partner with us for the most efficient strategy to actualize your biotech and pharmaceutical products sooner and improve the lives of patients worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Apr 13, 2022 at 12:02 PM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cerba Research. (2022, April 13). Alleviating the complexity of rare disease research. News-Medical. Retrieved on November 27, 2022 from https://www.news-medical.net/whitepaper/20220405/Alleviating-the-complexity-of-rare-disease-research.aspx.

  • MLA

    Cerba Research. "Alleviating the complexity of rare disease research". News-Medical. 27 November 2022. <https://www.news-medical.net/whitepaper/20220405/Alleviating-the-complexity-of-rare-disease-research.aspx>.

  • Chicago

    Cerba Research. "Alleviating the complexity of rare disease research". News-Medical. https://www.news-medical.net/whitepaper/20220405/Alleviating-the-complexity-of-rare-disease-research.aspx. (accessed November 27, 2022).

  • Harvard

    Cerba Research. 2022. Alleviating the complexity of rare disease research. News-Medical, viewed 27 November 2022, https://www.news-medical.net/whitepaper/20220405/Alleviating-the-complexity-of-rare-disease-research.aspx.

Other White Papers by this Supplier